Navigation Links
BioMS Medical to present at UBS Global Life Sciences Conference
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York.

WHEN: Monday September 22nd at 10:00am (Eastern Time)

WHERE: Grand Hyatt New York, New York

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of comp
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. BioMS Medical announces its intention to renew a normal course issuer bid
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. BioMS Medical Announces Second Quarter 2008 Results
5. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
6. BioMS Medical to present at BMO Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at Jefferies Healthcare Conference
9. BioMS Medical to present at 2008 BIO International Convention
10. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medical announces first quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... the, Nikon Ti Inverted Microscope System to Provide Advanced System ... ... MELVILLE, N.Y., Jan. 29 Nikon Instruments, Inc., (http://www.nikoninstruments.com ... systems, which seamlessly integrates with the new Ti-E,research inverted microscope. ...
... REDWOOD CITY, Calif., Jan. 29 Codexis(R), Inc., ... manufacturing,processes, today introduced the Codex(TM) MicroCyp Plate, a ... companies to more,rapidly identify and synthesize drug metabolites ... Plate is being introduced this week at Informex,2008 ...
... SAN DIEGO, Jan. 29 ChemDiv, Inc., ... announced today,that it has entered into a ... CA. Applying its expertise in medicinal and ... and developing,novel antibacterial compounds. Financial terms of ...
Cached Biology Technology:Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 2Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 3Nikon Instruments Launches Fully-Automated A1 Confocal Laser Microscope Series 4Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds 2ChemDiv and Achaogen Enter Into a Discovery Collaboration 2
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... new study published in Cancer Research shows ... and colon cancers—can promote the development of skin cancers ... and survival of sun-damaged skin cells. , Previously considered ... proteins called sirtuins that help regulate genomic stability and ... SIRT6 helps repair DNA damage, which can lead to ...
(Date:10/14/2014)... planet,s leading questions is how to produce enough food ... The Food and Agriculture Organization of the United Nations ... next 40 years to feed a growing global population, ... rise in food production. Plants—grains, cereals, fruits, vegetables, ... Current research must tap into our knowledge of ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... of human beings. Now Tel Aviv University has developed ... lead to new antibiotics and powerful bacteria-based "green" pesticides ... by Prof. Eshel Ben-Jacob of Tel Aviv University,s Department ... Sirota-Madi says that their results deepen science,s knowledge of ...
... cell scientists, bioethicists and experts in law and public ... counter secrecy and self interest. The recommended measures focus ... of intellectual property related to stem cells. In ... British city where members first met in 2006lists five ...
... and monitoring Crohn,s disease. It is a stressful procedure in ... into the large intestine. MRI scans are therefore often used ... and how it is responding to treatment. TU Delft is ... an objective, quantitative method for assessing these MRI scans. The ...
Cached Biology News:The genius of bacteria 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 2Recommendations issued to counter patent, proprietary barriers to sharing stem cell data 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
... The product contains 5 ... coated with the monoclonal BerEP4 ... EpCAM (epithelial cell adhesion molecule). ... samples of 2 x 10e7 ...
MOUSE ANTI HUMAN FACTOR I...
Superior homology search software - in all the flavours of blast, with increased sensitivity and speed. Free windows version for academic use....
GFX PCR DNA,Gel Band Purif,100, 1 EA. Category: Nucleotide Sample Handling....
Biology Products: